News News - 2023 Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023 Continue Reading
News News - 2023 Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001 Continue Reading
News News - 2022 Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy Continue Reading
News News - 2022 Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022 Continue Reading
News News – 2021 Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies Continue Reading
News News – 2021 Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-Driven Cancers Continue Reading
